December 8, 2025Blood

Trials in progress: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase I/II trial shows safety of CPX-351 in AML patients ineligible for HSCT, indicating potential maintenance benefits with low-dose treatment.

Low-dose CPX-351 treatment yielded a favorable safety profile, benefiting patients in complete remission.
Overall, the trial aims to evaluate health quality of life through geriatric assessments and MRD detection.
This phase I/II observational analysis investigates outcomes of newly diagnosed AML patients without transplant eligibility.
Further investigation needed for long-term effects and applicability beyond initial trial results.

McKay et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase I/II trial shows safety of CPX-351 in AML patients ineligible for HSCT, indicating potential maintenance benefits with low-dose treatment.